Ja Hye Myung
Papers
1
Total Citations
49
H-Index
1
About
Ja Hye Myung is a leading cancer researcher whose work focuses on the molecular mechanisms of cell cycle regulation and the development of next-generation targeted therapies. Her major contributions center on elucidating the concept of anaphase catastrophe—a novel cell death mechanism triggered by aberrant mitosis—and translating this into therapeutic strategies for lung cancer. In her highly cited 2016 study, Myung investigated CCT68127, a potent next-generation CDK2/9 inhibitor, demonstrating its superior efficacy over first-generation agents like seliciclib. Her research revealed that selective CDK2/9 inhibition induces multipolar anaphase and apoptosis specifically in lung cancer cells with supernumerary centrosomes, offering a targeted approach to exploit tumor-specific vulnerabilities. With 49 citations, this seminal work has established a new paradigm for CDK inhibitor design and provided a mechanistic rationale for anaphase catastrophe as a therapeutic endpoint. Myung’s innovative contributions continue to shape the development of precision oncology strategies, bridging fundamental cell cycle biology with clinical applications in drug-resistant cancers.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016